TrialJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2025

A Prospective Phase II Trial of First-Line Osimertinib for Patients With EGFR Mutation-Positive NSCLC and Poor Performance Status (OPEN/TORG2040).

Tomoya Fukui et al.PubMed ↗Publisher ↗

No numbers read from the abstract.